Nektar Therapeutics (NASDAQ:NKTR) Hits New 52-Week Low – Here’s Why

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) hit a new 52-week low on Thursday. The company traded as low as $32.89 and last traded at $33.4510, with a volume of 237,090 shares traded. The stock had previously closed at $34.42.

Key Headlines Impacting Nektar Therapeutics

These are some of the NKTR headlines that stood out recently:

  • Positive Sentiment: HC Wainwright raised its EPS forecasts across several periods, reflecting narrower expected losses: FY2026 to ($7.06) from ($7.49), FY2027 to ($8.40) from ($8.83), and its estimates for FY2028 and FY2029 also improved. Its 2030 forecast increased to positive EPS of $0.59 from $0.35. The firm reiterated its Buy rating and $185 price target. These revisions may support sentiment toward NKTR. Nektar Therapeutics analyst estimates
  • Neutral Sentiment: Despite the improvements, HC Wainwright still forecasts losses through 2029, so the positive outlook depends on Nektar’s ability to execute its longer-term plans and reach profitability.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on NKTR shares. Leerink Partners started coverage on Nektar Therapeutics in a research report on Monday, October 12th. They set an “outperform” rating and a $130.00 price objective on the stock. Wall Street Zen lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 14th. HC Wainwright restated a “buy” rating and issued a $185.00 price target on shares of Nektar Therapeutics in a report on Friday, October 2nd. JPMorgan Chase & Co. assumed coverage on shares of Nektar Therapeutics in a research report on Friday, August 21st. They issued a “neutral” rating and a $65.00 price objective on the stock. Finally, TD Cowen upgraded shares of Nektar Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $130.33.

Read Our Latest Stock Report on NKTR

Nektar Therapeutics Trading Down 4.1%

The stock has a 50-day moving average price of $46.15 and a two-hundred day moving average price of $64.53. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -5.10 and a beta of 1.44.

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last announced its earnings results on Thursday, November 12th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.07) by $0.44. Nektar Therapeutics had a negative return on equity of 29.31% and a negative net margin of 339.67%. The company had revenue of $9.39 million for the quarter, compared to analyst estimates of $10.27 million. Research analysts predict that Nektar Therapeutics will post -7.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nektar Therapeutics

Several hedge funds have recently modified their holdings of the stock. KBC Group NV purchased a new position in shares of Nektar Therapeutics in the 1st quarter valued at approximately $52,000. State of Wyoming acquired a new stake in Nektar Therapeutics in the 1st quarter worth approximately $67,000. Sterling Capital Management LLC boosted its stake in Nektar Therapeutics by 507.2% in the 3rd quarter. Sterling Capital Management LLC now owns 1,099 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 918 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Nektar Therapeutics by 35.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,160 shares of the biopharmaceutical company’s stock worth $128,000 after purchasing an additional 560 shares during the last quarter. Finally, Great Lakes Advisors LLC purchased a new stake in Nektar Therapeutics during the 2nd quarter worth approximately $206,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

About Nektar Therapeutics

(Get Free Report)

Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.

Read More

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.